Maligned Canadian cannabis producer CannTrust Holdings (NYSE:CTST,TSX:TRST) is facing a class-action lawsuit update.

On Monday (February 3), Henein Hutchison, speaking for a group of Ontario-based law firms, issued a statement claiming that the Ontario Superior Court of Justice has confirmed that the group can carry on with a proposed securities class action targeting the marijuana company.

The legal action is tied to CannTrust’s improper cannabis growing operations, which were discovered by regulators in July 2019. The misstep led to an eventual license suspension for the company and the damage to its reputation caused to the larger Canadian cannabis market to take a hit.

Shares of CannTrust fell in both New York and Toronto during Monday’s session. The company finished the first trading day of the week priced at US$1.04 and C$1.37.

In the pre-market trading portion of Tuesday (February 4), the company was already down an additional almost 4 percent on the New York Stock Exchange. However, just after the official start of the session, it bounced back with a 2.92 percent increase in Toronto and a 1.44 percent marginal jump in New York.

Since the original illegitimate growing discovery, which brought the dismissal of the firm’s former CEO and of its co-founder, shares of CannTrust have dropped in value dramatically by over 70 percent in both New York and Toronto.

stock chart for CannTrust Holdings

“Cases like this show the power of class actions to bring access to justice to individuals who place their savings at risk in the stock markets,” Dimitri Lascaris, a lawyer working within the group representing the investors raising the suit, said in a statement.

Marie Henein, another lawyer working on the lawsuit, said the case will be brought in front of the courts “at the earliest opportunity.”

In an emailed statement, a CannTrust spokesperson declined to comment for this story.

In its most recent mandated bi-weekly update to investors, CannTrust made no mention of the progress for the class-action suit. The company signaled it still has a cash balance of nearly C$175 million.

The legal action comes from CannTrust investors who bought shares of the company between June 1, 2018, and September 17, 2019, according to the parameters of the suit, in addition to investors who participated in a prospectus offering from the company in May 2019.

In addition to CannTrust, the suit also includes the underwriters of the CannTrust offering: Merrill Lynch Canada, Citigroup Global Markets Canada, Credit Suisse Securities (Canada), RBC Dominion Securities, Jefferies Securities and Canaccord Genuity.

The raise was designed to secure CannTrust with US$170 million in gross proceeds thanks to the sale of just over 5.4 million shares.

Tax audit and advisory firm KPMG is also included as a defendant in this case, given its role as CannTrust’s auditor.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less